Cost-effectiveness analysis comparing degarelix with leuprolide in hormonal
therapy for patients with locally advanced prostate cancer.
Author(s): Hatoum HT(1), Crawford ED, Nielsen SK, Lin SJ, Marshall DC.
Affiliation(s): Author information:
(1)Hind T Hatoum & Company, 155 N Harbor Drive, 1912, Chicago, IL 60601, USA.
hthatoum@sbcglobal.net
Publication date & source: 2013, Expert Rev Pharmacoecon Outcomes Res. , 13(2):261-70
Degarelix, approved in the USA in 2008, is a gonadotropin-releasing hormone
antagonist, representing one of the latest additions to androgen deprivation
therapy (ADT). ADT is used as first-line therapy for locally advanced or
metastatic prostate cancer with the aim to reduce testosterone to castrate
levels. Like other gonadotropin-releasing hormone-antagonists, degarelix
treatment results in rapid decrease in luteinizing hormone, follicle-stimulating
hormone and testosterone levels without the associated risk of flare. Using one
registration trial for degarelix with leuprolide as the active control, a
cost-effectiveness analysis with a Markov model and a 20-year time horizon found
the incremental cost-effectiveness ratio for degarelix to be
US$245/quality-adjusted life years. Degarelix provides a cost-effective treatment
for ADT among patients with locally advanced prostate cancer.
|